Aquestive Therapeutics
AQST
37 hedge funds and large institutions have $13.6M invested in Aquestive Therapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 12 closing their positions.
5,100% more call options, than puts
Call options by funds: $52K | Put options by funds: $1K
2.24% less ownership
Funds ownership: 29.79% → 27.56% (-2.2%)
20% less funds holding
Funds holding: 46 → 37 (-9)
27% less capital invested
Capital invested by funds: $18.7M → $13.6M (-$5.11M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$93.8K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$59.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.4K |
| 4 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
+$4.7K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$411K |
| 2 |
Millennium Management
New York
|
-$403K |
| 3 |
Goldman Sachs
New York
|
-$32K |
| 4 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
-$30K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$28.1K |
AQST Hedge Fund Activity: Q4 2022 in Review
37 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2022, worth a combined $13.6M — down 27% from $18.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of AQST and 4 opened new positions — a net loss of 8 holders — while 12 trimmed existing stakes and 5 added.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $93.8K. The largest seller was Renaissance Technologies, cutting an estimated $411K.
- 37 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2022, down from 46 in Q3 2022.
- Funds reported $13.6M of Aquestive Therapeutics stock for Q4 2022, down 27% quarter-over-quarter.
- 4 funds opened new Aquestive Therapeutics positions in Q4 2022 and 12 closed out, a net change of -8 holders.
- The largest Aquestive Therapeutics buyer in Q4 2022 was Schonfeld Strategic Advisors, an estimated $93.8K added.
- The largest Aquestive Therapeutics seller in Q4 2022 was Renaissance Technologies, an estimated $411K sold.
Based on aggregated 13F filings for Q4 2022.